|
Ataxia-Telangiectasia (AT)
|
ATM 11q23
|
P041-025R
|
€ 228
|
|
Ataxia-Telangiectasia (AT)
|
ATM 11q23
|
P041-050R
|
€ 456
|
|
Ataxia-Telangiectasia (AT)
|
ATM 11q23
|
P042-025R
|
€ 228
|
|
Ataxia-Telangiectasia (AT)
|
ATM 11q23
|
P042-050R
|
€ 456
|
|
Breast cancer susceptibility
|
CHEK2 22q12, ATM , PTEN, TP53
|
P190-025R
|
€ 228
|
|
Breast cancer susceptibility
|
CHEK2 22q12, ATM , PTEN, TP53
|
P190-050R
|
€ 456
|
|
Breast cancer susceptibility
|
CHEK2 22q12, ATM , PTEN, TP53
|
P190-100R
|
€ 912
|
|
Breast cancer, hereditary
|
BRCA2, CHEK2
|
P045-025R
|
€ 228
|
|
Breast cancer, hereditary
|
BRCA2, CHEK2
|
P045-050R
|
€ 456
|
|
Breast cancer, hereditary
|
BRCA2, CHEK2
|
P045-100R
|
€ 912
|
|
Breast cancer, hereditary
|
BRCA2
|
P077-025R
|
€ 228
|
|
Breast cancer, hereditary
|
BRCA2
|
P077-050R
|
€ 456
|
|
Breast cancer, hereditary
|
BRCA2
|
P077-100R
|
€ 912
|
|
Breast cancer, hereditary
|
BRCA1
|
P087-025R
|
€ 228
|
|
Breast cancer, hereditary
|
BRCA1
|
P087-050R
|
€ 456
|
|
Breast cancer, hereditary
|
BRCA1
|
P087-100R
|
€ 912
|
|
Breast cancer, hereditary
|
BRCA2 13q12.3
|
P090-025R
|
€ 228
|
|
Breast cancer, hereditary
|
BRCA2 13q12.3
|
P090-050R
|
€ 456
|
|
Breast cancer, hereditary
|
BRCA2 13q12.3
|
P090-100R
|
€ 912
|
|
Breast cancer
|
BRCA1 region
|
P239-025R
|
€ 228
|
|
Breast cancer
|
BRCA1 region
|
P239-050R
|
€ 456
|
|
Breast cancer
|
BRCA1 region
|
P239-100R
|
€ 912
|
|
CDH1 or E-cadherin
|
CDH1 16q22.1
|
P083-025R
|
€ 228
|
|
CDH1 or E-cadherin
|
CDH1 16q22.1
|
P083-050R
|
€ 456
|
|
CDH1 or E-cadherin
|
CDH1 16q22.1
|
P083-100R
|
€ 912
|
|
Cancer
|
PTEN 10q23
|
P225-025R
|
€ 228
|
|
Cancer
|
PTEN 10q23
|
P225-050R
|
€ 456
|
|
Cancer
|
PTEN 10q23
|
P225-100R
|
€ 912
|
|
Cancer
|
BRIP1 17q22, CHEK1 11q22
|
P240-025R
|
€ 228
|
|
Cancer
|
BRIP1 17q22, CHEK1 11q22
|
P240-100R
|
€ 912
|
|
Colon cancer, hereditary non-polyposis (HNPCC)
|
MLH1 3p21.3, MSH2 2p21
|
P248-025R
|
€ 228
|
|
Colon cancer, hereditary non-polyposis (HNPCC)
|
MLH1 3p21.3, MSH2 2p21
|
P248-050R
|
€ 456
|
|
Colon cancer, hereditary non-polyposis (HNPCC)
|
MLH1 3p21.3, MSH2 2p21
|
P248-100R
|
€ 912
|
|
Colon cancer, stomach cancer (hereditary)
|
1p34 and 15q13
|
P378-025R
|
€ 228
|
|
Colon cancer, stomach cancer (hereditary)
|
1p34 and 15q13
|
P378-050R
|
€ 456
|
|
Colon cancer, stomach cancer (hereditary)
|
1p34 and 15q13
|
P378-100R
|
€ 912
|
|
Familial melanoma
|
CDKN2A, CDKN2B, CDK4, MITF E318K
|
P419-025R
|
€ 228
|
|
Familial melanoma
|
CDKN2A, CDKN2B, CDK4, MITF E318K
|
P419-050R
|
€ 456
|
|
Familial melanoma
|
CDKN2A, CDKN2B, CDK4, MITF E318K
|
P419-100R
|
€ 912
|
|
Fanconi Anemia
|
RAD50
|
P260-025R
|
€ 228
|
|
Fanconi Anemia
|
RAD50
|
P260-050R
|
€ 456
|
|
Fanconi Anemia
|
RAD50
|
P260-100R
|
€ 912
|
|
Fanconi anemia (FA)
|
FANCD2. 3p25.3, PALB2 16p12
|
P057-025R
|
€ 228
|
|
Fanconi anemia (FA)
|
FANCD2. 3p25.3, PALB2 16p12
|
P057-050R
|
€ 456
|
|
Fanconi anemia (FA)
|
FANCD2. 3p25.3, PALB2 16p12
|
P057-100R
|
€ 912
|
|
Fanconi anemia complementation group B
|
FANCB Xp22
|
P113-025R
|
€ 228
|
|
Fanconi anemia complementation group B
|
FANCB Xp22
|
P113-050R
|
€ 456
|
|
Fanconi anemia complementation group B
|
FANCB Xp22
|
P113-100R
|
€ 912
|
|
Gorlin syndrome
|
PTCH 9q22.3
|
P067-025R
|
€ 228
|
|
Gorlin syndrome
|
PTCH 9q22.3
|
P067-050R
|
€ 456
|